Evaluating TL-925 for treating allergic conjunctivitis
Official title: A Single-Center, Randomized, Double-masked, Vehicle-controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model
Run by Telios Pharma, Inc. · NCT06686472 · Data updated 2026-11-12
This study is testing if a new eye drop called TL-925 can help people with allergic conjunctivitis feel better compared to a placebo.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 66 (estimated) |
| Sponsor | Telios Pharma, Inc. Industry-sponsored |
| Locations | 1 site (Memphis, Tennessee) |
| Status | Recruiting |
| Started | October 3, 2024 |
| Main results expected | December 10, 2024 |
| Study ends | December 10, 2024 |
| Registry record updated | November 13, 2024 |
| Trial ID | NCT06686472 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a documented history of ocular allergies and a positive reaction to specific allergens.
✕Probably not a fit
Patients with ongoing ocular infections or recent ocular surgeries may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 clinical trial is designed to assess the efficacy of TL-925, a topical ophthalmic eye drop, in treating allergic conjunctivitis. Approximately 66 eligible participants will be randomly assigned to receive either TL-925 or a placebo in a double-masked manner. The study will utilize a conjunctival allergen challenge model to evaluate the treatment's effectiveness over a defined screening and treatment period.
Why it matters
Potential benefit: If successful, this treatment could provide significant relief for patients suffering from allergic conjunctivitis.
How similar studies have gone: While this approach is being evaluated in this trial, similar studies have shown promise in treating allergic conjunctivitis with other interventions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals aged 18 years or older * Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study. * Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the past 60 months. * Calculated best-corrected visual activity of 0.7 LogMAR or better * Positive bilateral CAC reaction Exclusion Criteria: * Any systemic or ocular disease currently producing ocular redness and/or ocular discomfort, or that may interfere with the conduct of the study. * Any ocular surgical intervention within the last 3 months OR refractive surgery within the last 6 months * Any ongoing ocular infection (bacterial, viral or fungal)
Where it's running
-
Telios Investigative Site
Memphis, Tennessee, United States Recruiting
Study contacts
- Study coordinator: John Mei
- Email: jmei@teliospharma.com
- Phone: (650) 542-0136
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cat-allergy eye allergy treatment with REGN-2Cat and study drugs in adults and kids
This trial tests fel d 1 monoclonal antibodies (freneslerbart and mevonlerbart) alone or together to see if they reduce cat‑induced allergic conjunctivitis symptoms compared with placebo in adults and children.
-
TL-925 eye drops for allergic conjunctivitis
This trial will test whether TL-925 eye drops relieve allergy-related eye redness and itching in adults with seasonal or perennial allergic conjunctivitis using a controlled allergen challenge.
-
Analyzing tear samples to identify eye surface conditions
This study is testing tear samples from patients with eye surface conditions like dry eye and allergies to see if they can identify unique markers for these issues.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.